CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

In recognition of World Cancer Day 2025, AstraZeneca reaffirms its commitment to advancing early detection, innovative ...

The U.K. government is defending its negotiations with AstraZeneca (AZN), after the pharmaceutical company dropped a planned $558M investment ...

PHARMACEUTICAL giant AstraZeneca has scrapped plans for a £450m (US$559m) upgrade to its vaccine manufacturing facility in ...

In particular, the charges have targeted two lawmakers typically seen as pharma foes: Sens. Bernie Sanders (I-Vt.) and ...

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

Havant MP Alan Mak has accused the Labour Government of 'botching' a £450m investment deal with pharmaceutical giant ...

Wall Street falls as Trump imposes tariffs, but not as badly as feared The threat of a punishing trade war sent Wall Street ...

If you purchased or acquired securities in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like ...

The firm scrapped its £450m investment despite the government's offer of support, the government says.

Science minister Sir Chris Bryant said the Government feels regretful about the plan being ditched and ‘would prefer to have got this over ...